{"result": "\n{\n    \"title\": \"Hydrocortisone and the CORTICUS Study\",\n    \"summary\": \"The community is centered around the use of hydrocortisone in the treatment of septic shock, with significant contributions from the CORTICUS study and the Surviving Sepsis Campaign. Key entities include hydrocortisone, fludrocortisone, and the CORTICUS study, which collectively explore the efficacy and safety of corticosteroid therapy in septic shock management.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical role of hydrocortisone in managing life-threatening conditions like septic shock and the influence of the CORTICUS study on clinical guidelines.\",\n    \"findings\": [\n        {\n            \"summary\": \"Hydrocortisone's role in septic shock treatment\",\n            \"explanation\": \"Hydrocortisone is extensively studied and used in the context of septic shock, a severe and potentially life-threatening condition. It is administered to patients with septic shock to evaluate its impact on mortality and secondary outcomes. Clinical trials have been conducted to assess its potential to prevent or resolve septic shock, with a focus on its hemodynamic effects and the speed of resolution. While hydrocortisone is used in the treatment of septic shock with the aim of reducing mortality and improving patient survival, studies have shown mixed results regarding its effectiveness in decreasing mortality rates. Despite these mixed outcomes, hydrocortisone remains a significant component of therapeutic strategies for managing septic shock [Data: Entities (36); Relationships (122, 201, 196, 206, 207)].\"\n        },\n        {\n            \"summary\": \"CORTICUS study's influence on clinical practice\",\n            \"explanation\": \"The CORTICUS study, also known as the Corticosteroid Therapy of Septic Shock study, is a clinical trial that investigated the effects of low-dose hydrocortisone therapy on patients with septic shock. The study reported that while septic shock was reversed more quickly with the administration of hydrocortisone, it did not significantly reduce mortality. The primary focus of the CORTICUS study was to evaluate both the efficacy and safety of this treatment approach in managing septic shock. The findings of the CORTICUS study have influenced clinical guidelines and practices, particularly in the context of the Surviving Sepsis Campaign [Data: Entities (378); Relationships (163, 195, 443, 468, 858)].\"\n        },\n        {\n            \"summary\": \"Surviving Sepsis Campaign's guidelines\",\n            \"explanation\": \"The Surviving Sepsis Campaign is an international initiative aimed at reducing mortality from sepsis and septic shock through the development and dissemination of comprehensive guidelines and protocols. These guidelines include the management of sepsis and septic shock, with specific recommendations such as the 6-hour bundle of care and the endorsement of early goal-directed therapy (EGDT) as a strategy to decrease mortality in septic shock patients. The campaign also advises on nonresuscitation aspects of care and recommends maintaining a mean arterial pressure target of at least 65 mm Hg during the initial resuscitation of patients with septic shock. Additionally, the guidelines provide recommendations for blood transfusion in patients with septic shock. The Surviving Sepsis Campaign's guidelines are followed by study sites globally, underscoring its role in standardizing care and improving outcomes for sepsis patients worldwide [Data: Entities (110); Relationships (165, 467, 193, 468, 466)].\"\n        },\n        {\n            \"summary\": \"Combination therapy with fludrocortisone\",\n            \"explanation\": \"Fludrocortisone is a synthetic corticosteroid and mineralocorticoid used in combination with hydrocortisone in various clinical trials, including the APROCCHSS trial and the Annane study, to treat conditions such as septic shock and adrenal insufficiency. In these studies, it was administered as a daily dose of 50 μg orally. Despite its use in these trials, fludrocortisone was previously shown to be ineffective in the context of the specific trial mentioned. It was also compared against a placebo in the study to evaluate its efficacy. The combination of hydrocortisone and fludrocortisone remains a common therapeutic approach in managing septic shock [Data: Entities (37); Relationships (123, 190, 210, 211, 212)].\"\n        },\n        {\n            \"summary\": \"Impact of hydrocortisone on delirium and superinfection\",\n            \"explanation\": \"Hydrocortisone is a treatment that has been studied to assess its impact on the development of delirium. Research indicates that hydrocortisone treatment is associated with a lower risk of developing delirium, suggesting its potential benefit in managing or preventing this condition. However, the use of hydrocortisone was also associated with an increased incidence of superinfection, highlighting the need for careful consideration of its risks and benefits in clinical practice [Data: Entities (400, 615); Relationships (198, 204, 108)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n36,HYDROCORTISONE,\"Hydrocortisone is a corticosteroid medication and natural hormone used in the treatment of severe sepsis, septic shock, and adrenal insufficiency. It is often combined with fludrocortisone for treating adrenal insufficiency and septic shock. In the context of the study, hydrocortisone was administered as a 50-mg intravenous bolus every 6 hours to assess its effects on inflammation, immune responses, hyperglycemia, delirium, and survival in patients with septic shock. The study involved administering hydrocortisone to 190 patients to evaluate its impact on severe sepsis or septic shock, with a specific focus on comparing its effects to a placebo. Additionally, it was administered to 344 patients who received dopamine and 326 patients who received norepinephrine. The medication was evaluated in the CORTICUS study and was prepared by Rotexmedica for use as an adjunctive therapy in patients with septic shock, with the aim of studying its effects on mortality and secondary outcomes.\",21\n378,CORTICUS STUDY,\"The CORTICUS study, also known as the Corticosteroid Therapy of Septic Shock study, is a clinical trial that investigated the effects of low-dose hydrocortisone therapy on patients with septic shock. The study reported that while septic shock was reversed more quickly with the administration of hydrocortisone, it did not significantly reduce mortality. The primary focus of the CORTICUS study was to evaluate both the efficacy and safety of this treatment approach in managing septic shock.\",12\n110,SURVIVING SEPSIS CAMPAIGN,\"The Surviving Sepsis Campaign is an international initiative aimed at reducing mortality from sepsis and septic shock through the development and dissemination of comprehensive guidelines and protocols. These guidelines include the management of sepsis and septic shock, with specific recommendations such as the 6-hour bundle of care and the endorsement of early goal-directed therapy (EGDT) as a strategy to decrease mortality in septic shock patients. The campaign also advises on nonresuscitation aspects of care and recommends maintaining a mean arterial pressure target of at least 65 mm Hg during the initial resuscitation of patients with septic shock. Additionally, the guidelines provide recommendations for blood transfusion in patients with septic shock. The Surviving Sepsis Campaign's guidelines are followed by study sites globally, underscoring its role in standardizing care and improving outcomes for sepsis patients worldwide.\",9\n37,FLUDROCORTISONE,\"Fludrocortisone is a synthetic corticosteroid and mineralocorticoid used in combination with hydrocortisone in various clinical trials, including the APROCCHSS trial and the Annane study, to treat conditions such as septic shock and adrenal insufficiency. In these studies, it was administered as a daily dose of 50 μg orally. Despite its use in these trials, fludrocortisone was previously shown to be ineffective in the context of the specific trial mentioned. It was also compared against a placebo in the study to evaluate its efficacy.\",7\n400,DELERIUM,\"DELERIUM is a condition characterized by confusion and reduced awareness. It has been studied in relation to cortisol levels and hydrocortisone treatment. In particular, delirium is assessed in ICU patients, and its frequency can be affected by hydrocortisone treatment.\",4\n644,DROTRECOGIN ALFA,\"A drug used in the APROCCHSS trial, also known as activated protein C, to treat septic shock\",2\n377,ANNANE,Researcher involved in a study that showed hydrocortisone improved survival and reversal of septic shock in patients with relative adrenal insufficiency,1\n399,CRITICAL ILLNESS–RELATED CORTICOSTEROID INSUFFICIENCY (CIRCI),\"CIRCI is a condition affecting cortisol levels in critically ill patients, impacting the development of septic shock\",1\n603,ROTEXMEDICA,Rotexmedica is the company that prepared the hydrocortisone vials used in the study,1\n604,KLOCKE VERPACKUNGS SERVICE,Klocke Verpackungs Service is responsible for coding and masking the vials of hydrocortisone and placebo centrally,1\n615,SUPERINFECTION,An increased incidence of new infections observed in the hydrocortisone group during the study,1\n599,SCHUMER,Schumer conducted a study that led to the acceptance of high-dose corticosteroids as therapy for septic shock,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n122,SEPTIC SHOCK,HYDROCORTISONE,\"Hydrocortisone is extensively studied and used in the context of septic shock, a severe and potentially life-threatening condition. It is administered to patients with septic shock to evaluate its impact on mortality and secondary outcomes. Clinical trials have been conducted to assess its potential to prevent or resolve septic shock, with a focus on its hemodynamic effects and the speed of resolution. While hydrocortisone is used in the treatment of septic shock with the aim of reducing mortality and improving patient survival, studies have shown mixed results regarding its effectiveness in decreasing mortality rates. Despite these mixed outcomes, hydrocortisone remains a significant component of therapeutic strategies for managing septic shock.\",91\n163,SEPTIC SHOCK,CORTICUS STUDY,The CORTICUS study evaluated the treatment of septic shock,82\n165,SEPTIC SHOCK,SURVIVING SEPSIS CAMPAIGN,The Surviving Sepsis Campaign offers guidelines for the treatment of septic shock.,79\n123,SEPTIC SHOCK,FLUDROCORTISONE,\"Fludrocortisone is a medication used in the treatment of septic shock, often in combination with hydrocortisone, to help reduce mortality. Despite its use, there have been instances where fludrocortisone was not administered in certain trials due to previous findings suggesting it was ineffective for some patients with septic shock. However, its combination with hydrocortisone remains a common therapeutic approach in managing this critical condition.\",77\n201,HYDROCORTISONE,TRIAL,The trial involved administering hydrocortisone to one group of patients,61\n467,SURVIVING SEPSIS CAMPAIGN,EGDT,\"The Surviving Sepsis Campaign is an initiative aimed at reducing mortality in patients with sepsis and septic shock. One of the key strategies endorsed by the campaign is Early Goal-Directed Therapy (EGDT), which is specifically designed to decrease mortality in patients suffering from septic shock. Although the decline in in-hospital mortality for septic shock began before the introduction of the Surviving Sepsis Campaign, the campaign has continued to promote EGDT as an essential component of its efforts to improve patient outcomes.\",60\n109,PLACEBO,HYDROCORTISONE,Hydrocortisone and placebo were the two treatments compared in the trial,52\n111,PLACEBO,CORTICUS STUDY,A placebo was used as a control in the CORTICUS study,43\n196,HYDROCORTISONE,SEVERE SEPSIS,Hydrocortisone was tested to see if it could prevent the development of septic shock in patients with severe sepsis,38\n108,PLACEBO,DELERIUM,Placebo was used as a control to compare the effects of hydrocortisone on delirium,35\n195,HYDROCORTISONE,CORTICUS STUDY,The CORTICUS study primarily evaluated the use of hydrocortisone as a treatment. The study found that hydrocortisone was effective in reversing septic shock more quickly.,33\n192,HYDROCORTISONE,NOREPINEPHRINE,Hydrocortisone was administered to patients who received norepinephrine,31\n205,HYDROCORTISONE,APROCCHSS,The APROCCHSS trial tested the efficacy of hydrocortisone in treating septic shock,31\n206,HYDROCORTISONE,INTENSIVE CARE UNIT (ICU),Hydrocortisone treatment was associated with lower mortality at ICU discharge in the trial,31\n193,HYDROCORTISONE,SURVIVING SEPSIS CAMPAIGN,\"The Surviving Sepsis Campaign, which provides guidelines for the management of sepsis, includes hydrocortisone as a recommended treatment option. Specifically, the campaign suggests the use of hydrocortisone for patients experiencing refractory septic shock, highlighting its role in managing this severe condition.\",30\n207,HYDROCORTISONE,HOSPITAL,Hydrocortisone treatment was associated with lower mortality at hospital discharge in the trial,30\n443,MULTICENTER TRIAL,CORTICUS STUDY,The CORTICUS study was conducted as a multicenter trial,28\n190,HYDROCORTISONE,FLUDROCORTISONE,\"Hydrocortisone and fludrocortisone are pharmaceutical agents that have been used together in various therapeutic and clinical trial settings. They were trial agents compared against placebos and have been specifically utilized in the treatment of septic shock and adrenal insufficiency. Notably, their combination was employed in the APROCCHSS trial, which focused on their efficacy in treating septic shock. These agents are often used in replacement therapy to manage conditions like septic shock, highlighting their importance in critical care settings.\",28\n191,HYDROCORTISONE,DOPAMINE,Hydrocortisone was administered to patients who received dopamine,28\n197,HYDROCORTISONE,SEVERE SEPSIS OR SEPTIC SHOCK STUDY,Hydrocortisone was one of the treatments evaluated in the study,28\n198,HYDROCORTISONE,DELERIUM,\"Hydrocortisone is a treatment that has been studied to assess its impact on the development of delirium. Research indicates that hydrocortisone treatment is associated with a lower risk of developing delirium, suggesting its potential benefit in managing or preventing this condition.\",25\n200,HYDROCORTISONE,RCT,RCTs are conducted to evaluate the effectiveness of hydrocortisone in treating septic shock,24\n208,HYDROCORTISONE,DROTRECOGIN ALFA,Hydrocortisone was tested alongside drotrecogin alfa in the APROCCHSS trial,23\n194,HYDROCORTISONE,ANNANE,Annane's study showed that hydrocortisone improved survival and reversal of septic shock,22\n199,HYDROCORTISONE,CRITICAL ILLNESS–RELATED CORTICOSTEROID INSUFFICIENCY (CIRCI),Hydrocortisone was studied in patients with CIRCI to assess its effects on septic shock,22\n202,HYDROCORTISONE,ROTEXMEDICA,Rotexmedica prepared the hydrocortisone used in the study,22\n203,HYDROCORTISONE,KLOCKE VERPACKUNGS SERVICE,Klocke Verpackungs Service was responsible for coding and masking the hydrocortisone vials,22\n204,HYDROCORTISONE,SUPERINFECTION,The use of hydrocortisone was associated with an increased incidence of superinfection,22\n468,SURVIVING SEPSIS CAMPAIGN,CORTICUS STUDY,The Surviving Sepsis Campaign guidelines recommend practices that were evaluated in the CORTICUS study,21\n458,TRISS,SURVIVING SEPSIS CAMPAIGN,\"The TRISS trial evaluates blood transfusion thresholds, which are also addressed by the Surviving Sepsis Campaign\",20\n471,SURVIVING SEPSIS CAMPAIGN,APROCCHSS,The APROCCHSS trial focused on patients whose condition did not improve after initial resuscitation according to the Surviving Sepsis Campaign guidelines,19\n210,FLUDROCORTISONE,APROCCHSS,The APROCCHSS trial tested the efficacy of fludrocortisone in treating septic shock,17\n211,FLUDROCORTISONE,INTENSIVE CARE UNIT (ICU),Fludrocortisone treatment was associated with lower mortality at ICU discharge in the trial,17\n858,CORTICUS STUDY,CORTICOTROPIN,Corticotropin tests were used to assess patient response in the CORTICUS study,16\n212,FLUDROCORTISONE,HOSPITAL,Fludrocortisone treatment was associated with lower mortality at hospital discharge in the trial,16\n856,CORTICUS STUDY,CLINICAL EVALUATION COMMITTEE,The committee assessed antiinfective treatments in the CORTICUS study,15\n57,INDEPENDENT DATA AND SAFETY MONITORING BOARD,CORTICUS STUDY,The board monitored data safety and integrity during the CORTICUS study,15\n241,INTENSIVE CARE UNITS,CORTICUS STUDY,The CORTICUS study was conducted in 52 participating intensive care units,15\n470,SURVIVING SEPSIS CAMPAIGN,SEPSISPAM,The SEPSISPAM trial was conducted to evaluate the guidelines recommended by the Surviving Sepsis Campaign,15\n656,CLINICALTRIALS.GOV,CORTICUS STUDY,The CORTICUS study is registered on ClinicalTrials.gov,14\n818,ETHICS COMMITTEE,CORTICUS STUDY,The ethics committee approved the protocol for the CORTICUS study,14\n466,SURVIVING SEPSIS CAMPAIGN,PARTICIPATING SITES,The participating sites adhered to the Surviving Sepsis Campaign guidelines for nonresuscitation aspects of care,14\n857,CORTICUS STUDY,SCHUMER,\"Schumer's study influenced the use of corticosteroids, which was further evaluated in the CORTICUS study\",13\n209,FLUDROCORTISONE,ANNANE STUDY,Fludrocortisone was used in the Annane study to treat patients,11\n469,SURVIVING SEPSIS CAMPAIGN,GERMAN SEPSIS SOCIETY,The German Sepsis Society guidelines align with the Surviving Sepsis Campaign,11\n213,FLUDROCORTISONE,DROTRECOGIN ALFA,Fludrocortisone was tested alongside drotrecogin alfa in the APROCCHSS trial,9\n869,RICHMOND AGITATION-SEDATION SCALE,DELERIUM,The Richmond Agitation-Sedation Scale is used to assess delirium in ICU patients,6\n870,CONFUSION ASSESSMENT METHOD FOR THE ICU,DELERIUM,The Confusion Assessment Method for the ICU is used to diagnose delirium in critically ill patients,6\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}